IP-001 is a proprietary glycan polymer that acts both as an antigen depot and a potent immune activator capable of stimulating immunological responses against cancer and infectious diseases.

Antigen Depot Effect

IP-001 is a macromolecule with a cationic backbone that generates a depot effect, enhancing antigen retention at the injection site and allowing for a prolonged interaction with the immune system.

Recruitment of Innate Immune Cells

IP-001 increases innate immune cell infiltration into the injection site and activates multiple myeloid cell populations, especially antigen-presenting cells (APCs) like dendritic cells (DCs) and macrophages.

Activated by IP-001

Innate Immune System
Downstream Adaptive Immune System

Activation by IP-001

The ignited systemic, adaptive immune response seeks out and eliminates its target throughout the body.

CD8+ T Cell

Like all T cells, these are white blood cells that originate from the bone marrow and develop in the thymus. CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), are the primary effectors of cell-mediated adaptive immune responses once activated by antigen-presenting cells (APCs). CTLs are armed with cell-death-inducing surface ligands and effector molecules to kill aberrant cells. They are one of the most potent immune effector cells and are capable of killing cancer cells and virally infected cells.

CD4+ T Cell

This subtype of T cells expresses the signaling protein CD4 and recognizes peptides presented to them on APCs. They are classified as “helper” T cells because, rather than acting as a killer of damaged cells, they trigger the body's immune response to aberrant cells through other cells (like CD8+ cells). Depending on the environmental signal they receive, CD4 T cells can differentiate into various helper phenotypes that can direct the specific types of adaptive immune responses following antigen presentation.

B Cell

B cells are a type of white blood cell that originates in the bone marrow. They can act as APCs but can also differentiate into clones of plasma cells that secrete a specific antibody upon encountering a particular foreign antigen. Some B cells turn into long-lasting memory cells that can produce antibodies in a much larger quantity within a shorter timeframe on subsequent encounters of the same antigen. This mechanism is an important basis of vaccination against multiple infectious diseases.

This is a depiction of the story and potential of IP-001. More information is available upon request, and additional clinical trials are critical to demonstrate clinical efficacy in specific oncology indications.
IP-001 is a proprietary glycan polymer that acts both as an antigen depot and a potent immune activator capable of stimulating immunological responses against cancer and infectious diseases.

Antigen Depot Effect

IP-001 is a macromolecule with a cationic backbone that generates a depot effect, enhancing antigen retention at the injection site and allowing for a prolonged interaction with the immune system.

Recruitment of Innate Immune Cells

IP-001 increases innate immune cell infiltration into the injection site and activates multiple myeloid cell populations, especially antigen-presenting cells (APCs) like dendritic cells (DCs) and macrophages.

Activated by IP-001

Innate Immune System
Downstream Adaptive Immune System

Activation by IP-001

The ignited systemic, adaptive immune response seeks out and eliminates its target throughout the body.

CD8+ T Cell

Like all T cells, these are white blood cells that originate from the bone marrow and develop in the thymus. CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), are the primary effectors of cell-mediated adaptive immune responses once activated by antigen-presenting cells (APCs). CTLs are armed with cell-death-inducing surface ligands and effector molecules to kill aberrant cells. They are one of the most potent immune effector cells and are capable of killing cancer cells and virally infected cells.

CD4+ T Cell

This subtype of T cells expresses the signaling protein CD4 and recognizes peptides presented to them on APCs. They are classified as “helper” T cells because, rather than acting as a killer of damaged cells, they trigger the body's immune response to aberrant cells through other cells (like CD8+ cells). Depending on the environmental signal they receive, CD4 T cells can differentiate into various helper phenotypes that can direct the specific types of adaptive immune responses following antigen presentation.

B Cell

B cells are a type of white blood cell that originates in the bone marrow. They can act as APCs but can also differentiate into clones of plasma cells that secrete a specific antibody upon encountering a particular foreign antigen. Some B cells turn into long-lasting memory cells that can produce antibodies in a much larger quantity within a shorter timeframe on subsequent encounters of the same antigen. This mechanism is an important basis of vaccination against multiple infectious diseases.

This is a depiction of the story and potential of IP-001. More information is available upon request, and additional clinical trials are critical to demonstrate clinical efficacy in specific oncology indications.